Our company name, Centricity Vision, Inc., reflects our company’s expertise, expanded product offerings in cataract surgery, and continued commitment to customers and patients.
As a global ophthalmic technology company, we take pride in delivering innovative solutions that help surgeons across the world achieve surgical and clinical excellence.
Currently, we’re focusing on our unprecedented ZEPTO IOL Positioning System™. Designed to enhance the precision and efficiency of cataract surgery, the ZEPTO IOL Positioning System™ is the first and only device that creates an instantaneous capsulotomy for precise, 360-degree IOL overlap and improved outcomes. ZEPTO is ideal for premium IOLs and complex cases that require enhanced precision. ZEPTO also provides significant cost and time savings with easy workflow integration and increased efficiency per case.
Moving forward, we’ll leverage this microsurgical technology to create a suite of products for refractive cataract surgery management. Our relentless commitment to developing solutions of the highest quality and technological sophistication is uncompromising—as is our dedication to assisting physicians in delivering the best care to patients.
In this Healio Video Perspective from Eyecelerator@ASCRS, Rob Thornhill discusses the FDA 510(k) clearance of the ZEPTOLink IOL Positioning System and the benefits the system may provide cataract surgeons.
Centricity Vision Inc., a global ophthalmic technology company, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the new ZEPTOLink™ IOL Positioning System. The new platform seamlessly integrates the clinically proven ZEPTO precision pulse capsulotomy technology with any phacoemulsification (phaco) system to streamline cataract surgery.
A recent study found Zepto precision pulse capsulotomy offers significant advantages over manual capsulorhexis in treating white cataracts!
It’s an honor to be recognized for our ZEPTO IOL Positioning System’s ability to provide greater precision, efficiency, and affordability to practices everywhere!
Learn more about Dr. Shalesh Kaushal who recently adopted ZEPTO for his in-office surgical suite.
Centricity Vision Inc., a global ophthalmic technology company and developer of the ZEPTO IOL Positioning System™, today announced the launch of ZEPTO Plus™, a new, innovative addition to its handpiece portfolio. ZEPTO Plus provides a choice for surgeons who prefer a slightly larger capsulotomy created with the same clinically proven technology available with the current ZEPTO® handpiece.
Centricity Vision Inc., a global ophthalmic technology company and developer of the ZEPTO® Precision Cataract Surgery Platform, today announced the publication of a clinical study describing how to use Purkinje reflections at patient fixation for capsulotomy centration and 360-degree capsular overlap with the ZEPTO Platform to help achieve improved visual outcomes.
Centricity Vision Inc., a global ophthalmic technology company and developer of the ZEPTO® Precision Cataract Surgery Platform, today announced two product innovations under development, the ZEPTOLINK platform and ZEPTO 5.5 mm capsulotomy technology. The company has also appointed Leonard Borrmann, Pharm. D, to lead research and development.
Our CEO, Rob Thornhill, gave an exclusive interview to The Ophthalmologist before this year’s AAO meeting in New Orleans. See what Rob has to say about his vision for the company and his excitement at the difference being made by ZEPTO capsulotomy technology.
Centricity Vision Inc., a global ophthalmic technology company and developer of the ZEPTO® Precision Cataract Surgery Platform, announced Todd Pinkney has been named chief commercial officer (CCO) and will lead global commercialization of the ZEPTO Platform.
Our next generation of ZEPTO® is here with over 16 newly enhanced features! Experience the new handpiece and new power console – now optimized with improved usability, enhanced safety and for strong capsulotomies with a 360° IOL overlap.
Centricity Vision is proud to be featured in the July edition of Ophthalmology Management with the next generation of ZEPTO® Spotlight Technology & Technique article. Click to open the PDF of the article.
Centricity Vision, Inc., a global ophthalmic technology company dedicated to delivering solutions that help surgeons achieve surgical and clinical excellence, today announced that Jim Mazzo has been appointed to the company’s Board of Directors. Mazzo is one of the ophthalmic industry’s best known and most well respected business leaders with over 40 years of proven experience. “I am excited to join Centricity Vision’s Board of Directors and look forward to working with this exceptional team to increase global access to the ZEPTO Platform,” said Mazzo.
Dr. Ehsan Sadri and Rob Thornhill discuss the benefits of the Zepto Precision Cataract Surgery device in delivering automated, precise, circular, and centered capsulotomies – how their business model evolved during COVID-19 and the future direction for the company.
Centricity Vision, Inc., formerly known as Mynosys Cellular Devices, Inc., a global ophthalmic technology company dedicated to delivering products that help surgeons optimize outcomes in refractive surgery, today announced a new executive leadership team, along with a new company name.
REFERENCE 1: Thompson V. Streamlined method for anchoring cataract surgery and intraocular lens centration on the patient’s visual axis. J Cataract Refract Surg. 2018;44(5):528-533.
President & CEO
Rob is a start-up and large company medical device executive with equity fund-raising, business development, clinical study, and successful exit transactional experience. He has deep commercial operational experience with teams of up to 200 employees. Prior to joining Centricity Vision, Inc., Rob served as the founding CEO of Tear Film Innovations, Inc.,–manufacturer of the iLux treatment device for dry eye disease, which he led from seed stage through a Series B financing and then successfully sold to Alcon in 2018.
Chief Financial Officer
Louis has more than 26 years of experience as a senior financial executive with early-stage medical device companies. He was instrumental in raising in excess of $200 million in venture equity and debt as well as being actively involved in developing and implementing strategies for growth and maximizing shareholder value. Prior to joining Centricity Vision, Louis was CFO of ReVision Optics, Inc., a corneal inlay company. Prior experience included serving as CFO and participating in the sale of 3F Therapeutics, Inc., a tissue heart-valve company, acquired by ATS Medical, Inc., EndiCOR Medical, Inc., a coronary catheter company, acquired by Ev3, Inc., and SenDx Medical, Inc., a critical care diagnostic company, acquired by Radiometer. Prior to joining SenDx, Louis served as a Senior Audit Manager with Ernst & Young.
Chief Commercial Officer
Todd Pinkney has more than 25 years of leadership experience in medical devices, biologics, and pharmaceuticals across all aspects of commercialization including sales, marketing, analytics, reimbursement and managed care. He has commercial expertise in start-up, turnaround, and mature companies with significant business development and capital fundraising exposure. Todd currently oversees all aspects of commercial strategy for Centricity Vision’s innovative ZEPTO IOL Positioning System™, a medical device designed to improve precision in cataract surgery.
Prior to joining Centricity Vision, Todd spent more than 7 years at Allergan (an AbbVie company), most recently as Executive Director of Marketing where he managed the company’s $700 million Surgical and Therapeutics Glaucoma Franchise, including the commercial launch of XEN® Surgical Treatment System. Todd joined Allergan in 2011 as a Product Director for RESTASIS® and achieved double-digit annual growth and more than $1 billion in net sales.
Previously, Todd held commercial leadership roles at Genentech, Bristol-Myers Squibb and Merck. He earned an M.B.A. from Temple University and a B.S. degree from the University of Pittsburgh. When time permits, he enjoys spending time with family and friends, fulfilling his passion as a pilot and educating others about marine conservation as a volunteer Master Scuba Diver Instructor.
Head of Research and Development
Dr. Leonard R. Borrmann brings a wealth of product development, clinical, and regulatory expertise to Centricity Vision leading R&D initiatives for the company. Dr. Borrmann joined Johnson & Johnson in 2017 with the acquisition of Abbott Medical Optics where he was the Divisional Vice President of Research and Development and retired from J&J as Global Head of External Innovation in 2020. Prior to joining Abbott, Dr. Borrmann held positions of increasing responsibility in R&D, including Executive Vice President R&D with Advanced Medical Optics (acquired by Abbott in 2009). During his 13 years with AMO, Dr. Borrmann led the development and launch of more than 30 new products for AMO’s cataract, refractive and corneal businesses. Prior to joining AMO, Dr. Borrmann was CEO and director for a series of venture-backed biotech companies and had a 15-year career at Allergan Pharmaceuticals Inc., where he held positions of increasing responsibility in Clinical Research, Marketing and Business Development, including Vice President of Business Development.
Dr. Borrmann earned his bachelor’s degree in Psychobiology and Doctor of Pharmacy degree from University of Southern California.
Vice President, RA and Quality Assurance
Nealen has more than 20 years of experience with start-ups to large medical device companies supporting regulatory affairs, quality assurance, and quality engineering. He gained FDA clearance and international registration of various types of devices ranging from single-use disposables to electro mechanical devices. Nealen established and maintained quality management systems that have been successfully audited and inspected by the FDA, notified bodies, and international entities. He was also involved with a handful of acquisitions, with the latest being the acquisition of Tear Film Innovation, Inc. by Alcon.